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Table. Rates of Stent Thrombosis
Any post-PCI AC
for routine
prophylaxis
(N¼436)
No post-PCI AC for
routine
prophylaxis
(N¼1,009)
Adjusted
HR [95%
CI]
Adjusted
p-Value
Acute
(24 hour)
stent
thrombosis
3 (0.7) 10 (1.0) 0.65 [0.13,
3.18]
0.59
Thirty-day
stent
thrombosis
7 (1.7) 20 (2.1) 0.97 [0.37,
2.53]
0.95
Post-PCI AC for
routine
prophylaxis with
pre-PCI UFH
(N¼325)
Pre-PCI UFH with
no post-PCI AC for
routine prophylaxis
(N¼623)
Unadjusted
HR [95%
CI]
Unadjusted
p-Value
Acute
(24 hour)
stent
thrombosis
2 (0.6) 3 (0.5) 1.28 [0.21,
7.68]
0.78
Thirty-day
stent
thrombosis
5 (1.6) 8 (1.3) 1.20 [0.39,
3.65]
0.75
Only post-PCI AC
for routine
prophylaxis with
no pre-PCI UFH
(N¼111)
No pre-PCI UFH or
post-PCI AC for
routine prophylaxis
(N¼386)
Unadjusted
HR [95%
CI]
Unadjusted
p-Value
Acute
(24 hour)
stent
thrombosis
1 (0.9) 7 (1.9) 0.50 [0.06,
4.02]
0.50
Thirty-day
stent
thrombosis
2 (1.9) 12 (3.3) 0.57 [0.13,
2.55]
0.46
Values presented as n (%). Stent thrombosis was classiﬁed according to the Academic
Research Consortium deﬁnition of deﬁnite or probable. AC ¼ anticoagulation; PCI ¼ percu-
taneous coronary intervention; UFH ¼ unfractionated heparin.
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Intracoronary Bivalirudin Bolus During Primary Angioplasty Improves
Postprocedural Angiographic Flow and Myocardial Reperfusion Indexes
Alessandro Lupi1, Andrea Rognoni1, Gioel G. Secco2, Angelo S. Bongo1
1AOU Maggiore della Carità, Novara, Italy, 2University of Eastern Piedmont,
Novara, Italy
Background: Bivalirudin efﬁcacy in the very ﬁrst hours after primary PCI
has been questioned, due to increased acute stent thrombosis rates. Intracoronary
administration of the bivalirudin bolus might furnish an extremely high
local drug concentration without changing the global dose administered to the
patient, with a potential favorable effect over the pro-thrombotic milieu of the
infarct related artery. Thus we prospectively investigated the feasibility and
safety of intracoronary bivalirudin bolus administration during primary percuta-
neous coronary interventions (PCI), comparing it with the standard intravenous
route.
Methods: In 245 consecutive patients treated with primary PCI we administered
intracoronary bivalirudin bolus followed by standard intravenous infusion. Post-
procedural coronary blood ﬂow indexes and clinical reperfusion markers of these
patients were compared with a propensity score-matched cohort of primary PCI pa-
tients treated with standard intravenous bivalirudin bolus plus infusion.
Results: Our study suggests safety similar bleeding episodes were observed in the two
groups. However we observed better TIMI frame count values (14.7 vs 17.9,
P¼0.001), higher rates of  70% ST resolution (72.7 vs 60.0%, p¼0.004) and lower
postprocedural peak CK-MB levels (188.3  148.7 vs 242.1  208.1 Ui/dL,
P¼0.025) in the intracoronary bolus group. Acute stent thrombosis was observed only
in 3 cases, all in the intravenous bolus group (P¼NS). These results were substantially
conﬁrmed when the analysis was restricted to patients with evidence of an occluded
infarct related artery before PCI.
Conclusions: In the population studied intracoronary bivalirudin bolus during primary
PCI is safe and might improve results obtained through the standard intravenous route
over postprocedural coronary ﬂow and clinical myocardial reperfusion.B136 JACC Vol 64/11/Suppl B j September 13–1TCT-465
Safety and efﬁcacy of intracoronary bivalirudin administration during primary
angioplasty in comparison with a standard treatment with heparin and
provisional GP2b3a inhibitors
Alessandro Lupi1, Gioel G. Secco2, Andrea Rognoni1, Italo Porto3,
Maurizio Lazzero1, Angelo S. Bongo1
1AOU Maggiore della Carità, Novara, Italy, 2University of Eastern Piedmont,
Novara, Italy, 3San Donato Hospital, Arezzo, Italy
Background: Bivalirudin efﬁcacy in the very ﬁrst hours after primary PCI has been
questioned, due to increased acute stent thrombosis rates. Intracoronary adminis-
tration of the bivalirudin bolus might furnish an extremely high local drug con-
centration without changing the global dose administered to the patient, with a
potential favorable effect over the pro-thrombotic milieu of the infarct related artery.
We prospectively investigated the feasibility and safety of intracoronary bivalirudin
bolus administration during primary percutaneous coronary interventions (PCI),
comparing this strategy with the standard treatment based upon unfractionated
heparin (UFH) with provisional GP2B3A inhibitors (GPI) given through the intra-
venous route.
Methods: In 273 consecutive patients treated with primary PCI we administered
intracoronary bivalirudin bolus followed by standard intravenous infusion.
Postprocedural coronary blood ﬂow indexes and clinical reperfusion markers of
these patients were compared with a propensity score-matched cohort of primary
PCI patients treated with standard treatment with intravenous UFH 70Ui/Kg
(eventually with supplementary boluses to achieve an ACT>250sec) plus pro-
visional GPI.
Results: In the intracoronary bivalirudin group we observed better TIMI frame count
values (14.86.5 vs 16.99.3, P¼0.002), higher rates of  70% ST resolution (72.1
vs 44.5%, p¼0.001), lower incidence of no-reﬂow (7.0 vs 13.5%, p< 0.011) and a
trend for lower postprocedural peak CK-MB levels (140.0 [53.7-235.5] vs 159.2
[64.3-269.9] Ui/dL, p¼0.06). Moreover acute stent thrombosis (< 24h after PCI) was
observed in 11 cases, all in the UFH/GPI group (p¼0.009). Intracoronary bivalirudin
administration was safe, with less internal bleedings (3.7 vs 11.2%, p¼0.001) and less
need for transfusion (4.6 vs 1.1, p¼0.012). The results were substantially conﬁrmed
when the analysis was restricted to patients with an occluded infarct related artery
before PCI.
Conclusions: In the population studied intracoronary bivalirudin during primary PCI
was safe and might improve postprocedural coronary ﬂow, clinical myocardial
reperfusion and acute stent thrombosis rates, in comparison with the UFH plus pro-
visional GPI treatment.
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Bivalirudin Is Associated With Improved In-Hospital Outcomes After Peripheral
Arterial Interventions: An Observational Analysis On 23,934 Patients From The
PREMIER Hospital Database
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Background: Bivalirudin has been shown to reduce bleeding complications and
improve clinical outcomes in percutaneous coronary interventions but has not been
well studied in peripheral arterial interventions (PAI). We sought to evaluate the ef-
ﬁcacy and safety of bivalirudin as compared with unfractionated heparin (UFH) in
patients undergoing PAI by evaluating in-hospital outcomes from a large, real-world,
US hospital database of over 600 hospitals.
Methods: We identiﬁed all patients (n¼23,934) entered from 1/08-12/12 in the
PREMIER hospital database following PPI of the extremities and who were treated
with bivalirudin or UFH. In-hospital outcomes that were compared according to
treatment included death , myocardial infarction (MI), transfusion, stroke, amputation,
Major Adverse Cardiac Events (MACE: death, MI, stroke or amputation) and Net
Adverse Cardiac Events (NACE: MACE and transfusion). Propensity score matching
(PSM) was performed to control for selection bias.
Results: In-hospital outcomes for both the unadjusted population and the 3,649 PSM
pairs are shown in the Table. After PSM, bivalirudin was still associated with
signiﬁcantly lower rates of death, transfusion, MACE and NACE compared with
UFH. Linear regression modeling conﬁrmed these ﬁndings. Subgroup analysis in the
PSM population showed consistent treatment effect for all outcomes among
subgroups.7, 2014 j TCT Abstracts/Pharmacotherapy - Procedural Anticoagulants
